

Recent progress in commercial retinoids and carotenoids

J. Paust

BASF Aktiengesellschaft, Central Research Laboratory, 6700 Ludwigshafen, Germany

Abstract - Among the retinoids vitamin A has an exceptional position both by volume and in its field of application. The competing technical syntheses are discussed. The other retinoids namely (all *E*)- and (13 *Z*)-Retinoic acid and Etretinate are used as topical and systemic agents in dermatology.

Commercial synthetic carotenoids are mainly used as pigmenters for food in vivo; examples are egg yolk - and broiler pigmentation with β -apo-8'-carotenoid acid ethylester and pigmentation of farm-raised salmon with astaxanthin. Another field of application is direct coloration of food, e.g. of margarine with β -carotene. Presently β -carotene is booming as a substitute for vitamin A without teratogenic potential and as a biological antioxidant. Two strategies compete in manufacture of these carotenoids

- synthesis of β -apo-8'-carotenoids and β -carotene starting from vitamin A and its precursors followed by the stepwise oxidation of β -carotene to canthaxanthin and astaxanthin
- conversion of oxo-isophorone to C_{15} -phosphonium salts of different oxidation pattern in the β -ionone ring followed by Wittig condensation with C_{10} -dialdehyde.

INTRODUCTION

This report deals with the retinoids and carotenoids which are currently commercially available. It is in the nature of things that information on these cannot be very accurate or complete. The manufacturers of these products are competitors and thus not interested in revealing details of syntheses or capacities and manufacturing costs.

The two groups of products to be dealt with are summarized in Fig. 1 and 2. In total, four retinoids and six synthetic carotenoids have to date become of commercial importance.




Fig. 1. Commercial retinoids




Fig. 2. Commercial carotenoids

Among the retinoids, vitamin A occupies a special position. It is the most important product in terms of quantity sold. Vitamin A is mainly used in the feed- and foodstuffs sector: it ensures that livestock thrive and increases their resistance to infectious diseases (ref. 1).

The other retinoids are used in pharmaceuticals and employed in dermatology (ref. 2).

The main reason for producing the carotenoids is for their coloring properties; they are used on the one hand for direct coloring of foodstuffs and, on the other hand, for pigmentation of animal products by administration in the feed (ref. 3). In addition, it is becoming increasingly evident that the carotenoids have important roles in the animal and human body, besides their provitamin A activity (ref. 4).

VITAMIN A

Three companies are currently marketing vitamin A - Hoffmann-La-Roche, BASF AG and A.E.C. Rhône-Poulenc, and they produce about 3000 tonnes of this vitamin in total each year. In the form of a 15 % dispersible powder in which it is usually sold, 1 kg of vitamin A presently costs about US \$ 120. The sales world-wide are therefore about US \$ 360 million.

The syntheses used by the three manufacturers differ first in the basic chemicals used to synthesize pseudoionone and β -ionone, secondly in the type of intermediates used for chain extension and finally in the method of linkage employed to give the C_{20} final product.




Fig. 3. Synthesis of ψ -ionone from basic chemicals.





Fig. 4: Synthesis of citral by sigmatropic rearrangements

Pseudoionone is currently prepared from dehydro-linalool or citral (ref. 5, 6). Both precursors can be synthesized in several steps from basic chemicals, with sigmatropic rearrangements playing a crucial part (Fig. 3). A fascinating example is the double Cope rearrangement of the diene ether that is produced by acetalization and elimination from 3-methylbutenal (Fig. 4, ref. 7).

The C_6 and C_5 units employed for chain extension are also used to build up the polyene chain of carotenoids. The basic chemicals for the C_6 unit at Hoffmann-La-Roche are methyl



BASF AG

Fig. 5. Syntheses of 2-methyl-4-acetoxy-2-butenal (C₅ acetate).

vinyl ketone and acetylene (ref. 8). The C_5 unit used by Rhône-Poulenc is prepared from 3-methyl-1-butyne-3-ol via 3-methyl-2-butenal (ref. 9). At BASF the C_5 acetate is obtained by hydroformylation of 1-butenediol diacetate (Fig. 5, ref. 10) or by a synthesis based on oxirane and acetic acid via acetoxyacetaldehyde and condensation with propanal (ref. 11). Selective aldol condensations of this type give yields around 70 % in the presence of equimolar amounts of dimethylamine and acetic acid; the catalyst system can be recycled.

The polyene chain must be built up under particularly mild conditions. Hoffmann-La-Roche and Rhône-Poulenc achieve this by addition and elimination, the former by linking C_{14} and C_6 in a Grignard reaction (ref. 12) and the latter by Julia-synthesis from C_{15} and C_5 (ref. 13). At BASF AG, C_{15} is joined to C_5 in a one-step Wittig reaction (ref. 14, Fig. 6).




Fig. 6. Technical syntheses of vitamin A.

It is possible that, in future, syntheses which do not take place via the C_{13} intermediates pseudoionone and β -ionone will become important. Kuraray in Japan has done intensive work on the preparation of a cyclic C_{10} sulfone and an open-chain C_{10} aldehyde from myrcene and linalool respectively (ref. 15). The polyene chain is produced by linking the two units and preparing a β -alkoxy or δ -chloro- C_{10} -sulfone by base-promoted double elimination.

Vitamin A syntheses based on the $C_9 + C_6 + C_5$ scheme have not to my knowledge achieved any economic importance as yet (ref. 16). This synthetic approach is mentioned here nevertheless, because the $C_9 + C_6$ strategy has proven very useful in carotenoid syntheses.

Over the years the synthesis of the "immortal" agent vitamin A has been modified repeatedly. As shown in Fig. 7 new processes have been developed for the production of the C_{15} - and C_5 -precursors due to the availability of cheap basic chemicals.




Fig. 7. Developments in the synthesis of vitamin A.

Thus in 1960, 8 out of the 20 carbon atoms of vitamin A originated from acetylene and 6 from diketene or ethylacetoacetate (ref. 17). The remaining 6 carbon atoms stem from acetone. Thirty years later the situation has changed completely: 8 carbon atoms can be traced back to isobutene and 4 carbon atoms to formaldehyde (ref. 5, 6 and 10); acetone contributes 3 carbon atoms in positions 8, 9 and 19.

RETINOIDS

In contrast to vitamin A, which is an additive for human and animal foodstuffs, the other retinoids are pharmaceuticals (ref. 2). They have revolutionized the treatment of various skin disorders in the last decade. There has not yet been a breakthrough in tumor therapy, although inhibition of progression has been detected in animal experiments (ref. 18).

Retinoic acid (Tretinoin) is used topically for the treatment of acne but it is also becoming increasingly important for the treatment of skin damaged by UV-light (ref. 19). (13-*Z*)-Retinoic acid (Isotretinoin) can be used systemically, and this has made it possible for the first time to cure serious acne (ref. 20). Estimated sales in 1989 are US \$ 150 Mill. for Tretinoin and 100 Mill for Isotretinoin. The aromatic retinoid Etretinate has proven especially useful as a systemic agent for the treatment of inherited disorders of keratinization and certain types of psoriasis (ref. 21).




Fig. 8. Synthesis of Retinoic acid and (13 *Z*)-Retinoic acid

The retinoids which have been approved to date are synthesized in substantially the same way as vitamin A (Fig. 8, ref. 22). For example, (all *E*)- and (13 *Z*)-retinoic acid are obtained straightforwardly and in good yields from the C₁₅-phosphonium salt and C₅-aldehyde esters or the appropriate C₅-lactol. The oxidation of retinyl acetate to retinoic acid with silver oxide has been described and is preferred by manufacturers who do not have the C₁₅ and C₅ units available (ref. 23).

Fig. 9 gives a forecast of the future uses and market volumes of retinoids. World sales may exceed US \$ 1 billion in the 1990s. The prospects of this have recently led to a considerable intensification of research in this area. The main problems associated with this are well known in pharmaceutical research, namely (1) - Selection of actions from the almost bewildering variety displayed by retinoids. These include effects on cell differentiation, cell proliferation, sebum production and keratinization, in addition to immunostimulation, antiinflammatory effects and morphogenic activities (2) - Improvement of the therapeutic index by reducing undesired side effects, in particular reduction of the potential for irritation on topical application and reduction of the teratogenicity on systemic administration. With the availability of water-soluble β -glucuronide derivatives, problems of formulation and of absorption and transport of retinoids are overcome (ref. 24). Pelretin, which is a phenyl analog, has been shown in clinical tests to have a particularly low potential for irritation (ref. 25). The tetramethyltetralin derivatives are expected to have the most favorable spectrum of action to date for the treatment of sun-damaged skin (ref. 26).

Research into these questions now even extends into molecular biology. There is intensive investigation of the effects of retinoids on gene expression. Various retinoic acid receptors have been identified, and it is now possible to synthesize retinoids that are designed to fit these (ref. 27).

Indication	Exp. Sales →1995
Akne	→ 200 Mio US \$/a
Photoaged Skin	→ 500 Mio US \$/a
Hyperkeratosis	→ 150 Mio US \$/a
Skin Cancer	→ 250 Mio US \$/a
Neoplastic Diseases	→ 100 Mio US \$/a

Fig. 9. Potential development of the retinoid market

COMMERCIAL SYNTHESIS OF CAROTENOIDS

Carotenoid synthesis is still the preserve of Hoffmann-La-Roche and BASF AG, where vitamin A is manufactured, partly because from the outset these companies had the required range of precursors and experience in synthesizing polyene chains. Both companies initially concentrated on constructing the relatively large target molecules by using carbon-carbon linkage methods that were already proven in vitamin A chemistry; these were, in particular, (1) at Hoffmann-La-Roche, Grignard syntheses and enol ether condensations (ref. 9, 28) and (2) at BASF AG, ethynylations and Wittig olefin syntheses (ref. 12, 14). This type of synthetic strategy permits the processes to be simplified and makes multistage syntheses economical.

β -APO-CAROTENOIDS

The strategy is evident in the preparation of the β -apo-8'-carotenoids and β -carotene. The synthesis of β -apo-8'-carotenal at Hoffmann-La-Roche starts from the C_{14} aldehyde which gives, in two enol ether condensations, the C_{19} aldehyde. Grignard coupling with a C_6 unit is followed by another two enol ether condensations to give the C_{30} final product (ref. 29). The related β -apo-8'-ester is produced by condensation of the precursor C_{27} aldehyde with the appropriate Wittig C_3 ylide (ref. 30).




Fig. 10. Syntheses of β -apo-8'-carotenoids by enolether condensations

For BASF the obvious route was to prepare these carotenoids by using the Wittig reaction. When the double bonds are formed in position 11, 15 and 11' chemical yields > 90% of (E/Z)-isomers are obtained. Isomeric purity of the final products is controlled by conversion of the sterically hindered (Z)-components to the (all-E)-products with simultaneous crystallisation.

The β -apo-8'-carotenoids can be built up by $C_{20} + C_{10}$ Wittig reactions; both companies have reported this (ref. 31). The yields are comparable when retinal is linked to a C_{10} phosphonium salt or when retinyl triphenyl phosphonium salt is linked to the appropriate C_{10} aldehyde.

Syntheses based on the $C_{20} + C_{10}$ scheme appear short and elegant, but the preparation of the unsymmetrical C_{10} fragments is a multistage and thus costly process. It is therefore advantageous to prepare the β -apo-8'-carotenoids via β -apo-12'-carotenal. Three equally efficient pathways have been developed for the synthesis of this intermediate. These are Wittig reactions of (1) C_{15} phosphonium salt of the vitamin A synthesis with one equivalent of the symmetrical C_{10} dialdehyde (ref. 32), (2) C_{20} phosphonium salt with 2-methyl-butenedial-1-acetal (ref. 33, Fig. 11) and (3) retinal with the corresponding C_5 phosphonium chloride (ref. 34 Fig. 12). Retinal is obtained either by dehydrogenation of retinol with oxygen and TEMPO/ Cu_2Cl_2 as catalyst (ref. 35) or by Wittig reaction of the C_{15} phosphonium salt with another selectively protected C_5 dialdehyde, 3-methyl-butenedial-1-acetal (ref. 33, Fig. 12)

The C_{30} aldehyde and C_{30} ethyl ester target compounds are obtained from the C_{25} aldehyde by Wittig reaction with the C_5 phosphonium salt (ref. 34) or with an appropriate C_5 ethyl ester phosphonate (ref. 36).




Fig. 11 and 12. Retinal and β -apo-12'-carotenol in the synthesis of β -apo-8'-carotenoids

C_5 -INTERMEDIATES

3-Methyl-butenedial-1-acetal is easily obtained in two stages via glyoxal monoacetal by selective aldol condensation with propanal (ref. 33).

The C_5 ester component is obtained from 4-bromo-2-methyl-2-butenic acid ethyl ester and triethyl phosphite. The bromo-ester itself is synthesized (1) from methyl vinyl ketone and hydrocyanic acid via 2-methyl-2-hydroxy-3-butenic acid ethyl ester (ref. 37) by reaction with phosphorous tribromide or (2) from 2-methyl-3-butenitrile via the ethyl ester by addition of bromine and elimination of hydrogen bromide (ref. 38).

It is particularly economical to prepare all the C_5 components from the C_5 acetate intermediate that is used in the vitamin A process (Fig. 13).

Oxidation of the C_5 acetate with persulfuric acid in ethanol gives 4-hydroxy-2-methyl-2-butenic acid ethyl ester in 80 % yield. This is converted to the C_5 ethyl ester phosphonate in an obvious way.

The C_5 alcohol obtained by acetalization with a 1,3-diol and ester hydrolysis can be converted by reaction with phosgene and triphenyl phosphine into the C_5 phosphonium chloride in 80 % overall yield.

2-Methyl-butenedial-1-acetal is obtained by dehydrogenation of the C_5 alcohol with oxygen and the TEMPO/ Cu_2Cl_2 catalyst in 90 % yield. Other polyene allylic alcohols can also be converted into the aldehydes in this way (ref. 35). On Wittig reaction with the C_5 phosphonium chloride and hydrolysis the new C_5 aldehyde gives a 90 % yield of the symmetrical C_{10} dialdehyde which is the central part of many C_{40} carotenoids.




Fig. 13. Syntheses of C_6 -units starting from 4-acetoxy-2-methyl-butenal

To complete the group of β -apo-carotenoids of commercial interest, the synthesis of the C_{23} ketone citranaxanthin should be mentioned briefly. It is produced in about 90 % yield from β -apo-8'-carotenal by aldol condensation with acetone (ref. 39).

As the name indicates, the β -apo-carotenoids are formed by oxidative degradation of the C_{40} carotenoids, especially of β -carotene. As such they have always been present in our food and thus they are absolutely non-toxic in the natural concentrations. They are, therefore, highly suitable natural colorants for foods (ref. 1, 3). β -Apo- C_{30} ester (ref. 40) and citranaxanthin are used in the pigmentation of egg yolks and broilers, especially when the feedstuffs contain few natural xanthophylls. β -Apo- C_{30} aldehyde is used for direct coloring of foodstuffs, especially cheese. The total sales of this group of products are now about US \$ 50 million.

β -CAROTENE

β -Carotene has been produced by Hoffmann-La Roche since 1954 and by BASF since 1972. As with the β -apo-carotenoids, the syntheses of β -carotene in both companies lean heavily on the range of vitamin A precursors.




Fig. 14. Synthesis of β -carotene via enoether condensations




Fig. 15. Syntheses of β -carotene by the Wittig reaction

The developments outlined here are also reflected in the current and predicted sales of β -carotene. It is likely that β -carotene will soon overtake vitamin A. Capacity for more than 500 tonnes of β -carotene per year is currently planned or under construction worldwide. β -Carotene sales may reach US \$ 500 million towards the end of this century. Total sales of synthetic carotenoids are already in the order of US \$ 300 Mill. and may pass the US \$ 500 million mark in only about 5 years.

THE DEVELOPMENT OF CANTHAXANTHIN AND ASTAXANTHIN

In the 1950s it was discovered at Hoffmann-La-Roche that some of the canthaxanthin added to chicken feed is deposited in the egg yolk (ref. 50). Together with the xanthophylls which are naturally present or with β -apo- C_{30} ester, canthaxanthin gives the egg yolk an orange-red color which many consumers like. Carotenoids in the feed are also deposited in the bodies of poultry, being evident in the comb, beak and legs. This is not simply a cosmetic effect. It is now known that carotenoids enhance resistance to diseases and improve the shelf life and hatchability of eggs.

Commercial processes for the preparation of canthaxanthin are based on the oxidation of β -carotene and are thus developments of the very early investigations by Zechmeister and Karrer (Fig. 17, ref. 51). The principle is that β -carotene is halogenated in position 4 and then, via intermediates from solvolysis reactions, oxidized to canthaxanthin. In our variant of the process, β -carotene is oxidized with sodium chlorate in the presence of catalytic amounts of iodine. Yields of about 65 % of isolated (all E)-canthaxanthin are obtained in a dichloromethane/-water two-phase system (ref. 52).





Fig. 17. Synthesis of canthaxanthin by oxidation of β -carotene

Hoffmann-La-Roche subsequently took the initiative and synthesized canthaxanthin by the tried and tested $C_{15} + C_{10} + C_{15}$ scheme (Fig. 18, ref. 53). The novel 3-oxo- C_{15} phosphonium salt can be prepared by the $C_{13} + C_2$ and $C_9 + C_6$ routes. In both cases, the components are linked by addition of an organometallic compound to a carbonyl group. The C_9 unit can be obtained, for example, by selective reduction of the 4-oxo group to 4-hydroxy-6-oxo-isophorone (ref. 54); canthaxanthin yields of around 80 % are obtained from reaction of the C_{15} ylide with the C_{10} dial and the intermediate C_{25} aldehyde.






Fig. 19. Synthesis of astaxanthin by oxidation of canthaxanthin




Fig. 20. $C_{15} + C_{10} + C_{15}$ Synthesis of astaxanthin and zeaxanthin

It is known that wild salmon acquire astaxanthin and its esters from their food and store the pigment in their tissues. As aquaculture, especially of salmon, has intensified in recent years, there has been a rapid increase in interest in this carotenoid (ref. 55).

Synthetic astaxanthin has been marketed only by Hoffmann-La-Roche to date, and this company is responsible for all serious approaches to the synthesis of this carotenoid.

Astaxanthin can, in principle, be obtained by oxidation of other C_{40} carotenoids, for example from canthaxanthin by preparing the bis-silyl enol ether and oxidizing this with peracid (Fig. 19, ref. 56, 59). The protective groups prevent further oxidation to astacene.

Commercial astaxanthin synthesis uses the familiar $C_{15} + C_{10} + C_{15}$ scheme. The C_{15} unit is once again produced by the $C_9 + C_6$ route, and the C_9 acetonide is synthesized in three straightforward steps from oxo-isophorone (ref. 57). The same principle is used, via a C_9 unit prepared by fermentation, to synthesize (3R,3'R)-zeaxanthin (Fig. 20, ref. 58).

SYNTHETIC STRATEGIES

To summarize, there appear to be two fundamentally different strategies for the synthesis of these carotenoids (Fig. 21 and 22). On the one hand, β -carotene can be synthesized from vitamin A and triphenylphosphine and then oxidized specifically to canthaxanthin and astaxanthin. On the other hand, it is possible to prepare a specific trimethylcyclohexanone for each carotenoid (ref. 59). Alkylation with the C_6 component and conversion of the C_{15} unit into the phosphonium salt can be followed by Wittig reaction with the C_{10} dialdehyde to give the final products. This strategy is attractive because it is self-contained and, in principle, also permits the synthesis of vitamin A and the essential vitamin E precursor trimethylhydroquinone (ref. 60).

The two synthetic approaches allow certain conclusions to be drawn about the costs of manufacturing these carotenoids. It is possible to deduce from the "vertical" scheme that, although β -carotene should be accessible at very low cost from vitamin A, the more highly oxygenated carotenoids must be increasingly costly. By contrast, the "horizontal" scheme starting from oxo-isophorone is expected to have comparable costs of manufacture of the individual carotenoids at comparable levels of production.

As it turns out, a residence time of about 0,5 sec at 170 °C in mixing chamber I is adequate for obtaining a molecular solution from a β -carotene suspension with an average particle size of about 20 μm .

The molecular solution emerging from mixing chamber I is fed into mixing chamber II where it undergoes turbulent mixing with a cold aqueous solution of a protective polymer, resulting in precipitation of the carotenoid. Appropriate choice of the polymer makes it possible to limit the growth of the particles, after nucleation, to a size of about 0.1 μm . A dispersible powder can be obtained from the hydrosol by conventional methods, for example spraying, after the solvent has been removed by distillation.

Summing up it was shown how commercial carotenoids are produced starting from cheap basic chemicals and how these pure crystalline compounds are adapted to the different fields of application by sophisticated physicochemical operations. This results in a collection of toxicologically safe and high-quality food and feed-additives.

REFERENCES

1. J. A. Olson in L. J. Machlin, Handbook of Vitamins, Marcel Dekker, Inc., 1984; J. Ganguly, Biochemistry of Vitamin A, CRC Press, 1989.
2. H. Mayer, W. Bollag, R. Hänni and R. Rüegg, Experientia **34**, 1005 (1978); W. Bollag, J. Amer. Acad. Dermatol **9**, 797 (1983); M. B. Sporn, A. Roberts and D. S. Goodman, The Retinoids, Vol I, Academic Press, Orlando/USA, 1984.
3. J. C. Bauernfeind, Carotenoids as Colorants and Vitamin A Precursors, Academic Press, New York, 1981.
4. A. Bendich and J. A. Olson, The Faseb Journal, Vol. 3, 1927 (1989); A. Bendich, The Role of Antioxidant Vitamins on Immune Function, (Technical Symposium March 11, 1987, Daytona Beach, Florida); R. Peto, R. Doll, J. D. Buckley and M. B. Sporn, Nature **290**, 201 (1981).
5. R. Marbet and G. Saucy, US-Pat. 3 029 287 (1962); G. Saucy and R. Marbet, Helv. Chim. Acta **50**, 1158, 2091, 2095 (1967); W. Kimmel, N. W. Sax, S. Kaiser, G. G. Eichmann, G. O. Chase and A. Ofner, J. Org. Chem. **23**, 153 (1958).
6. E. E. Royals, Ind. Eng. Chem. **38**, 546 (1946); W. Oroschnik, G. Karmas and A. D. Mebane, J. Amer. Chem. Soc. **74**, 295 (1952); W. Hoffmann, Chem. Ztg. **97**, 23 (1973); W. Hoffmann, Seifen, Öle, Fette, Wächse **101**, 89 (1975); L. Janitschke, W. Hoffmann, L. Arnold, M. Stroezel and H.-J. Scheiper, Eur. Pat. 62 291 (1982).
7. A. F. Thomas, J. Amer. Chem. Soc. **91**, 3281 (1969); N. Götz and R. Fischer, Ger. Pat. 2 157 035 (1971); W. Leimgruber and D. H. Valentine, Ger. Pat. 2 411 530 (1974); Y. Ichikawa, M. Yamamoto and Y. Iwakani, Ger. Pat. Appl. 2 423 409 (1973); P. Chabardes and J. Chasal, Eur. Pat. 344 043 (1988).
8. O. Isler, H. Kläui and U. Solms, in W. H. Sebrell, R. S. Harris, The Vitamins, Vol. I, 102, Academic Press, New York, 1967; O. Isler, R. Rüegg and P. Schudel, Chimia **15**, 212 (1961).
9. J. Desmurs, Eur. Pat. 82 782 (1982); J. P. Decor, Ger. Pat. 2 708 282 (1977), 2 708 304 (1977); P. Chabardes, Eur. Pat. 240 431 (1987); C. G. Gardenas, U.S. Pat. 4 048 220 (1975); A. A. Gevorkyan, P. I. Kazaryan and S. V. Avakyan, Z. Org. Khimii, **23**, 1110 (1987).
10. W. Himmele and W. Aquila, Ger. Pat. 1 941 632 (1969); W. Himmele, W. Aquila and H.-I. Joschek, Ger. Pat. 2 004 675 (1970).
11. F. Merger, R. Fischer and R. Horler, Eur. Pat. 268 931 (1987).
12. O. Isler, W. Huber, A. Ronco and M. Kofler, Helv. Chim. Acta **30**, 1911 (1947); F. Kienzle, Pure Appl. Chem. **47**, 183 (1976); O. Isler, Pure Appl. Chem. **51**, 449 (1979); O. Isler and G. Brubacher, Vitamine I, G. Thieme Verlag Stuttgart, 1982; J. Paust, Ullmann's Encycl. techn. Chem., Bd. 23, 633 (1983); O. Isler, H. Kläui and U. Solms in W. H. Sebrell and R. S. Harris, The Vitamins, Vol. I, 102, Academic Press, New York, 1967.
13. M. Julia, Ger. Pat. 2 202 689 (1972); P. Chabardes, M. Julia and A. Menet, Ger. Pat. 2 305 267 (1973); P. Chabardes, M. Julia and A. Menet, Ger. Pat. 2 355 898 (1974); J.-P. Decor, Ger. Pat. 2 708 210 (1977); J.-P. Decor, Ger. Pat. 2 734 172 (1978); M. Julia and D. Arnold, Bull. Soc. Chim. France, 1973, 743, 746; A. Fischli and H. Mayer, W. Simon and H. J. Steller, Helv. Chim. Acta **59**, 397 (1976); G. L. Olson, H.-Ch. Cheung, K. D. Margan, Ch. Neukom und G. Saucy, J. Org. Chem. **41**, 3287 (1976); P. Chabardes, J. P. Decor and J. Varagnat, Tetrahedron **33**, 2799 (1977).

14. H. Pommer, Angew. Chem. **72**, 811 (1960); W. Reif and H. Grassner, Chem. Ing. Tech. **45**, 646 (1973); H. Pommer and A. Nürrenbach, Pure Appl. Chem. **43**, 527 (1975); G. Wittig and H. Pommer, Ger. Pat. 943 684 (1956), 950 552 (1956), 1 003 730 (1957); H. Pommer, G. Wittig and W. Sarnecki, Ger. Pat. 1 026 745 (1958); W. Sarnecki and H. Pommer, Ger. Pat. 1 046 046 (1958); K. Schleich and H.-J. Stoller, Ger. Pat. 2 636 879 (1975), 2 733 231 (1976).
15. J. Otera, T. Mandai and M. Kawada, Eur. Pat. 187 259 (1985); J. Otera, H. Misawa, T. Onishi, S. Suzuki and J. Fujita, J. Org. Chem. **51**, 3834 (1986); T. Onishi, T. Mori, S. Suzuki, M. Takigawa and K. Yamamoto, Eur. Pat. 348 813 (1989); T. Mori, S. Suzuki and T. Onishi, Eur. Pat. 349 991 (1989); J. Otera, Synthesis **1988**, 95; J. Otera, H. Misawa, T. Mandai, T. Onishi, S. Suzuki and Y. Fujita, Chem. Lett. **1985**, 1883.
16. G. L. Olson, H. C. Cheung, K. D. Margan, R. Berer and G. Saucy, Helv. Chim. Acta, **59**, 567 (1976).
17. M. F. Carroll, J. Chem. Soc., **1940**, 704, **1941**, 507; W. Kimmel, N. W. Sax, S. Kaiser, G. G. Eichmann, G. O. Chase and A. Ofner; J. Org. Chem. **23**, 153 (1958); Brit. Pat. 848 931 (1960).
18. A. S. Boyd, The Amer. J. Med. **86**, 568 (1989); M. Schäfer-Korting, Dtsch. Apoth. Z. **129**, 2039 (1989); C. E. Orfanos, R. Ehlert and H. Gollnick, Drugs, **34**, 459 (1987).
19. G. L. Peck, J. Amer. Acad. Dermatol., **15**, 829 (1986); A. M. Kligman, G. C. Grove, R. Hirose and J. J. Leyden, J. Amer. Acad. Dermatol. **15**, 836 (1986); J. S. Weiss, C. N. Ellis, J. T. Headington, T. Tincoff, T. A. Hamilton and J. J. Voorhess, J. Amer. Med. Assoc. **259**, 529 (1988); A. M. Kligman, Eur. Pat. 253 393 (1987); G. F. Bryce and S. S. Shapiro, Eur. Pat. 303 915 (1988) and 358 880 (1989).
20. G. L. Peck, T. G. Olsen, F. W. Yoder, J. S. Strauss, D. T. Downing, M. Pandya, D. Butkus and J. Arnaud-Battandier, The New England J. Med., **300**, 329 (1979); R. W. Lucek and W. A. Colburn, Clin. Pharmacokin. **10**, 38, (1985).
21. C. E. Orfanos, Hautarzt **40**, 123 (1989).
22. G. Pattenden and B. C. L. Weedon, J. Chem. Soc. (C), **1968**, 1984; H. Mayer, W. Bollag, R. Hänni and R. Rüegg, Experientia **34**, 1105 (1978); R. Lucci, Eur. Pat. 111 325 (1983).
23. R. Marbet, Ger. Pat. 2 061 507 (1970).
24. A. B. Barua and J. A. Olson, U.S. Pat. 4 855 463 (1989); A. B. Barua and J. A. Olson, J. Lipid Res. **26**, 1277 (1985).
25. M. I. Dawson, P. D. Hobbs, R. L. Chan, W. Chao and V. A. Fung, J. Med. Chem. **24**, 583 (1981); M. I. Dawson, R. Chan, P. D. Hobbs, W. Chao and L. J. Schiff, J. Med. Chem. **26**, 1182 (1983); H.-H. Wüst, F.-F. Frickel, J. Paust, K. Schmieder and A. Nürrenbach, U.S. Pat. 4 804 670 (1989).
26. M. Klaus, U.S. Pat. 4 396 553 (1983); H.-H. Wüst, B. Janssen, F.-F. Frickel and A. Nürrenbach, Eur. Pat. 232 779 (1987).
27. P. Dollé, E. Ruberte, P. Kastner, M. Petkovich, C. M. Stoner, L. J. Gudas and P. Chambon, Nature **342**, 702 (1989); A. Krust, P. Kastner, M. Petkovich, A. Zelent and P. Chambon, Proc. Natl. Acad. Sci. USA, **86**, 5310 (1989); Y. Taguefuji, Bitamin **63**, 411, (1989); H. Kageshika and K. Shudo, Farumashia **26**, 35 (1990); Y. Hashimoto, H. Kageshika, E. Kawachi and K. Shudo, Jpn. J. Cancer Res. **79**, 473 (1988); H. de Thé, M. M. Vivanco-Ruiz, P. Tiolles, H. Stunnenberg and A. Dejean, Nature **343**, 177 (1990).
28. O. Isler, R. Rüegg and P. Schudel, Chimia **15**, 212 (1951); H. Wiederkehr, Chimia **40**, 323 (1986).
29. R. Rüegg, H. Lindlar, M. Montavon, G. Saucy, S. F. Schaeren, U. Schwieter and O. Isler, Helv. Chim. Acta **42**, 847 (1959); R. Rüegg, M. Montavon, G. Ryser, G. Saucy, U. Schwieter and O. Isler, Helv. Chim. Acta **42**, 854 (1959).
30. O. Isler, W. Guex, R. Ruegg, G. Ryser, G. Saucy, U. Schwieter, M. Walter and A. Winterstein, Helv. Chim. Acta **42**, 864 (1959).
31. U. Schwieter, H. Gutmann, H. Lindlar, R. Marbet, N. Rigassi, R. Rüegg, S. F. Schaeren and O. Isler, Helv. Chim. Acta **49**, 369 (1966); Belg. Pat. 639 829 (1964); U.S. Pat. 3 113 961 (1963).
32. H. Pommer and A. Nürrenbach, Pure Appl. Chem. **43**, 546 (1975); H. Pommer, Angew. Chem. **89**, 440 (1977); S. Afr. Pat. 66/5814 (1967) and 67/1684 (1967); Ger. Pat. 1 210 780 (1963).

33. J. Paust, W. Reif and H. Schumacher, Liebigs Ann. Chem. 1976, 2194; Eur. Pat. 246 646 (1987) and 316 672 (1987).
34. S. M. Makin, Doklady Akad. Nauk SSSR, 138, 387 (1961); S. M. Makin, Zh. Obshch. Khim. 32, 3159 (1962); Ger. Pat. 1 211 616 (1966) and 1 216 862 (1966).
35. M. F. Semmelhack, C. R. Schmid, D. A. Cortes and C. S. Chou, J. Amer. Chem. Soc. 106, 3374 (1984); Ger. Pat. 3 705 785 (1987).
36. E. Buchta and F. Andree, Chem. Ber. 93, 1349 (1960); G. Pattenden and B. C. L. Weedon, J. Chem. Soc. C, 1997 (1968); Brit. Pat. 850 137 (1960).
37. Eur. Pat. 11 855 (1980).
38. Eur. Pat. 110 329 (1982); US Pat. 4 937 308 (1990).
39. H. Yokoyama and M. J. White, J. Org. Chem. 30, 2481 (1965).
40. US Pat. 2 940 856 (1960).
41. O. Isler, H. Lindlar, M. Montavon, R. Rüegg and P. Zeller, Helv. Chim. Acta 39, 249 (1956).
42. Ger. Pat. 924 247 (1956), 1 068 703 (1959), 1 068 705 (1959), all to BASF AG.
43. Ger. Pat. 1 068 709 (1959), 1 158 505 (1963) and 1 155 126 (1963), all to BASF AG; U. Schwieter, H. Gutmann, H. Lindlar, R. Marbet, N. Rigassi, R. Rüegg, S. F. Schaeren and O. Isler, Helv. Chim. Acta 49, 369 (1966); J. D. Surmatis, J. Gibas and R. Thommen, J. Org. Chem. 34, 3039 (1969); Neth. Pat. 6 909 081 (1969).
44. The Regents of the Univ. of California (Berkeley/CA-USA), Ger. Pat. 2 515 011 (1975).
45. H. J. Bestmann, C. Kisielowski and W. Distler, Angew. Chem. 88, 297 (1976).
46. A. Nürrenbach, J. Paust, H. Pommer, J. Schneider and B. Schulz, Liebigs Ann. Chem. 1146 (1977); Ger. Pat. 2 505 869 (1976).
47. A. Michaelis and H. von Soden, Liebigs Ann. Chem. 229, 295 (1885); Ger. Pat. 2 007 535 (1971).
48. G. Wunsch, K. Wintersberger and H. Geierhaas, Z. anorg. allg. Chem. 369, 33 (1969); Ger. Pat. 1 247 310 (1965) and 1 259 883 (1965).
49. C. H. Hennekens, Harvard Med. Sch. Boston/MASS. private communication.
50. Ger. Pat. 1 198 660 (1965).
51. F. J. Petracek and L. Zechmeister, J. Amer. Chem. Soc. 78, 1427 (1956); R. Entschel and P. Karrer, Helv. Chim. Acta 41, 402 (1958).
52. Ger. Pat. 2 534 805 (1975).
53. M. Rosenberger, P. McDougal and J. Bahr, Pure Appl. Chem. 51, 875 (1979).
54. Eur. Pat. 31875 (1980), 85 158 (1982) and 133 711 (1984) all to Hoffmann-La-Roche.
55. K. Schiedt, M. Vecchi, E. Glinz and T. Storebakken, Helv. Chim. Acta 71, 887 (1988); K. Schiedt, H. Mayer, M. Vecchi, E. Glinz and H. Storebakken, Helv. Chim. Acta 71, 881 (1988).
56. Eur. Pat. 101 597 (1983).
57. E. Widmer, R. Zell, E. A. Broger, Y. Grameri, H. P. Wagner, J. Dinkel, M. Schlageter and T. Lukac, Helv. Chim. Acta 64, 2436 (1981).
58. H. G. W. Leuenberger, W. Boguth, E. Widmer and R. Zell, Helv. Chim. Acta 59, 1832 (1976); E. Widmer, M. Soukup, R. Zell, E. Broger, H. P. Wagner and M. Imfeld, Helv. Chim. Acta 73, 861 (1990); M. Soukup, E. Widmer and T. Lukac, Helv. Chim. Acta 73, 868 (1990).
59. E. Widmer, Pure Appl. Chem. 57, 741 (1985); Ger. Pat. 3 735 211 (1987), 3 806 835 (1988); Eur. Pat. 311 408 (1986).
60. Belg. Pat. 849 560 (1975).
61. D. Horn, Angew. makromol. Chem. 166, 139 (1989).